Skip to main navigation menu Skip to main content Skip to site footer

Original article

Vol. 144 No. 0708 (2014)

Diagnosis and workup of 522 consecutive patients with neuroendocrine neoplasms in Switzerland

  • Marine Gouffon
  • Samuel Iff
  • Katrin Ziegler
  • Maria Larche
  • Christiane Schwarzenbach
  • John Prior
  • Maurice Matter
  • Christoph Stettler
  • François Pralong
Cite this as:
Swiss Med Wkly. 2014;144:w13924


BACKGROUND: Neuroendocrine neoplasms (NENs) are difficult to diagnose. We used SwissNET data to characterise NEN patients followed in the two academic centres of western Switzerland (WS), and to compare them with patients followed in eastern Switzerland (ES) as well as with international guidelines.

METHOD: SwissNET is a prospective database covering data from 522 consecutive patients (285 men, 237 women) from WS (n = 99) and ES (n = 423).

RESULTS: Mean ± SD age at diagnosis was 59.0 ± 15.7 years. Overall, 76/522 experienced a functional syndrome, with a median interval of 1.0 (IQR: 1.0–3.0) year between symptoms onset and diagnosis. A total of 51/522 of these tumours were incidental. The primary tumour site was the small intestine (29%), pancreas (21%), appendix (18%) and lung (11%) in both regions combined. In all, 513 functional imaging studies were obtained (139 in WS, 374 in ES). Of these, 381 were 111In-pentetreotide scintigraphies and 20 were 68Ga-DOTATOC PET. First line therapy was surgery in 87% of patients, medical therapy (biotherapy or chemotherapy) in 9% and irradiation in 3% for both regions together.

CONCLUSION: Swiss NEN patients appear similar to what has been described in the literature. Imaging by somatostatin receptor scintigraphy (SRS) is widely used in both regions of Switzerland. In good accordance with published guidelines, data on first line therapy demonstrate the crucial role of surgery. The low incidence of biotherapy suggests that long-acting somatostatin analogues are not yet widely used for their anti-proliferative effects. The SwissNET initiative should help improve compliance with ENETS guidelines in the workup and care of NEN patients.


  1. Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2008,26:3063–72.
  2. Gustafsson BI, Kidd M, Modlin IM Neuroendocrine tumors of the diffuse neuroendocrine system. Current opinion in oncology. 2008,20:1–12.
  3. Modlin IM, Oberg K, Chung DC, Jensen RT, de Herder WW, Thakker RV, et al. Gastroenteropancreatic neuroendocrine tumours. The lancet oncology. 2008,9:61–72.
  4. Massironi S, Sciola V, Peracchi M, Ciafardini C, Spampatti MP, Conte D. Neuroendocrine tumors of the gastro-entero-pancreatic system. World journal of gastroenterology: WJG. 2008,14:5377–84.
  5. Pape UF, Berndt U, Muller-Nordhorn J, Bohmig M, Roll S, Koch M, et al. Prognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumours. Endocrine-related cancer. 2008,15:1083–97.
  6. Klimstra DS, Modlin IR, Coppola D, Lloyd RV, Suster S. The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems. Pancreas. 2010,39:707–12.
  7. Salazar R, Wiedenmann B, Rindi G, Ruszniewski P. ENETS 2011 Consensus Guidelines for the Management of Patients with Digestive Neuroendocrine Tumors: an update. Neuroendocrinology. 2012,95:71–3.
  8. Solcia E, Klöppel G, Sobin LH. 2000 Histological typing of endocrine tumors. In: WHO international histological classification of tumors. Berlin: Springer. 56–70.
  9. Rindi G, Arnold R, Bosman FT. 2010 Nomenclature and classification of neuroendocrine neoplasmas of the digestive system. In: Bosman FT, Carneiro F, Hruban RH, Theise ND eds. WHO classification of tumors of the digestive system. Lyon: IARC.
  10. Pape UF, Perren A, Niederle B, Gross D, Gress T, Costa F, et al. ENETS Consensus Guidelines for the management of patients with neuroendocrine neoplasms from the jejuno-ileum and the appendix including goblet cell carcinomas. Neuroendocrinology. 2012,95:135–56.
  11. Jensen RT, Cadiot G, Brandi ML, de Herder WW, Kaltsas G, Komminoth P, et al. ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromes. Neuroendocrinology. 2012,95:98–119.
  12. Heitz PU, Komminoth P, Perren A, Klimstra DS, Dayal Y, Bordi C, et al. 2004 Pancreatic endocrine tumours: introduction. In: DeLellis RA, Lloyd RV, Heitz PU, Eng C eds. Pathology and genetics: tumours of endocrine organs WHO classification of tumours. Lyon: IARC Press. 177–82.
  13. Kloppel G, Couvelard A, Perren A, Komminoth P, McNicol AM, Nilsson O, et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: towards a standardized approach to the diagnosis of gastroenteropancreatic neuroendocrine tumors and their prognostic stratification. Neuroendocrinology. 2009,90:162–6.
  14. Ambrosini V, Campana D, Tomassetti P, Fanti S. (6)(8)Ga-labelled peptides for diagnosis of gastroenteropancreatic NET. European journal of nuclear medicine and molecular imaging. 2012;39(Suppl1):S52–60.
  15. Gabriel M, Decristoforo C, Kendler D, Dobrozemsky G, Heute D, Uprimny C, et al. 68Ga-DOTA-Tyr3–octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. Journal of nuclear medicine: official publication, Society of Nuclear Medicine. 2007;48:508–18.
  16. Oberg K Gallium-68 somatostatin receptor PET/CT: is it time to replace (111)Indium DTPA octreotide for patients with neuroendocrine tumors? Endocrine. 2012;42:3–4.
  17. Srirajaskanthan R, Kayani I, Quigley AM, Soh J, Caplin ME, Bomanji J. The role of 68Ga-DOTATATE PET in patients with neuroendocrine tumors and negative or equivocal findings on 111In-DTPA-octreotide scintigraphy. Journal of nuclear medicine: official publication, Society of Nuclear Medicine. 2010;51:875–82.
  18. Kanakis G, Kaltsas G Biochemical markers for gastroenteropancreatic neuroendocrine tumours (GEP-NETs). Best practice & research Clinical gastroenterology. 2012;26:791–802.
  19. Modlin IM, Gustafsson BI, Moss SF, Pavel M, Tsolakis AV, Kidd M. Chromogranin A--biological function and clinical utility in neuro endocrine tumor disease. Annals of surgical oncology. 2010,17:2427–43.
  20. O'Toole D, Grossman A, Gross D, Delle Fave G, Barkmanova J, O'Connor J, et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: biochemical markers. Neuroendocrinology, 2009;90:194–202.
  21. Oberg K Circulating biomarkers in gastroenteropancreatic neuroendocrine tumours. Endocrine-related cancer. 2011;18(Suppl 1):S17–25.
  22. Pavel M, Baudin E, Couvelard A, Krenning E, Oberg K, Steinmuller T, et al. ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology. 2012;95:157–76.
  23. Rinke A, Muller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2009;27:4656–63.

Most read articles by the same author(s)